Non-hormonal long-acting female contraceptive device (SBIR Phase II)
Official title: Development of a novel, non-hormonal female contraceptive device to submit IDE
Funded at Venova Technologies, INC. · NIH-11376556 · Data updated 2026-11-12
A women-led company is developing a non-hormonal, long-acting device to prevent pregnancy, aiming for future primate testing and clinical trials.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Venova Technologies, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | September 21, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,100,754 |
| NIH project number | 5R44HD111106-03 |
| Project ID | NIH-11376556 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include people seeking non-hormonal, long-acting contraception who want to avoid hormonal side effects.
✕Less likely to help
People who rely on hormonal contraception or who need highly reversible methods may not benefit as much.
What this research studies
This grant supports the development of a new non-hormonal contraceptive device that could offer long-acting protection without the side effects seen with hormonal methods. The project plans to advance engineering and testing toward primate studies and eventual human trials. It focuses on creating a safer, side-effect-free option for people who want more choices beyond hormonal methods.
Why it matters
Potential benefit: If successful, it could provide a long-acting, non-hormonal birth control option with fewer menstrual side effects.
How similar studies have gone: Previous non-hormonal options have limited evidence of long-acting efficacy; this represents an innovative approach with potential for significant impact.
Where this research is happening
-
Venova Technologies, INC.
Cambridge, United States Active
Researchers
- Principal investigator: Man, Emily — Venova Technologies, INC.
- Study coordinator: Man, Emily
Related research
Other NIH-funded projects on the same topics.
-
An integrated mobile health program to reduce SAVA and mental health problems among female sex workers in Kenya
A new mobile health program aims to help female sex workers in Kenya avoid substance abuse, violence, HIV, and depression by delivering group therapy, online resources, and a peer discussion space.
-
HIV in Women: How the virus hides and the immune system changes across life stages
This project looks at how HIV behaves differently in people from puberty through menopause, focusing on how hormones like estrogen may affect HIV persistence and immune responses.
-
Mobile health support to boost PrEP and contraception use among young women in Zambia
A mobile health program helps female university students in Zambia learn about and access HIV prevention and contraception.
-
Computational modeling of female hormone balance and drug responses
A new computational model uses patient-like data to predict how metabolic drugs will work in women across their hormonal cycles and different reproductive stages.
-
How PrEP Drugs Affect HIV Risk in Women and Reproductive Health
This project looks at how PrEP medicines work for women, and whether they influence pregnancy-related processes in the uterus.
-
How female eggs throw away most chromosomes during meiosis
A scientist at UC Davis is studying why only a quarter of chromosomes go into the egg during female reproductive cell division and how errors in this process can cause miscarriage or birth defects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.